Chembio Diagnostics

Chembio Diagnostics, Inc., together with its subsidiaries, develops, manufactures, and commercializes point-of-care (POC) diagnostic tests that are used to detect or diagnose diseases. The company offers tests for COVID-19, HIV and Syphilis, and Zika virus. It also develops tests for malaria, dengue, chikungunya, Chagas, ebola, leishmaniasis, lassa, marburg, leptospirosis, rickettsia, and Burkholderia diseases. The company sells its products under the STAT-PAK, SURE CHECK, STAT VIEW, and DPP trademarks, as well as sells its products directly through distributors to medical laboratories and hospitals, governmental and public health entities, non-governmental organizations, medical professionals, and retail establishments in the United States and internationally. It has collaboration agreements with Bill & Melinda Gates Foundation, The Paul G. Allen Family Foundation, The Oswaldo Cruz Foundation, and the Foundation for Innovative New Diagnostics, as well as U.S. government agencies, such as Centers for Disease Control and Prevention, the Biomedical Advanced Research and Development Authority of the U.S. Department of Health and Human Services, and the U.S. Department of Agriculture. Chembio Diagnostics, Inc. was founded in 1985 and is headquartered in Hauppauge, New York.

The mission of Chembio Diagnostics is to be the leading provider of POC tests that save human lives by providing rapid, simple to use, and accurate diagnosis of infectious diseases.

Chembio’s vision is to be the premier provider of POC technology to people in need of medical diagnostics in the US and around the world.

Chembio Diagnostics has been recognized by various organizations for their work in the field of medical diagnostics, including the Award for Innovation from the International Association for POC Diagnostics in 2017 and the Achievement Award from the Bioscience and Engineering Solutions Award from Frost & Sullivan in 2015.